Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – The Jakarta Post – Jakarta Post
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Noosa News23 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business21 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News19 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Noosa News21 hours ago150 jobs in doubt as Bega winds down peanut processing plants in Queensland